Aim Immunotech Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aim Immunotech Inc 's ROA in the first quarter of 2026?
Aim Immunotech Inc recorded a cumulative net loss of $-13 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -221.36%.

However, within the Healthcare sector 863 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4508, from total ROA ranking in the fourth quarter of 2025 at 5247.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	37.4 %	-32.83 %	-59.57 %	-73.73 %	-61.41 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-13	-14	-16	-16	-15
Return On Assets (TTM)	-221.36 %	-257.85 %	-257.36 %	-198.52 %	-137.76 %
AIM's Total Ranking	# 4508	# 5247	# 4662	# 4675	# 4647
Total Assets (TTM) in million	9	6	5	4	6
Seq. Total Assets Change	48.48 %	5.24 %	33.06 %	-33.91 %	-27.42 %
Seq. Net Income Change	-	-	-	-	-

AIM's 5 Years Annual ROA >> Back to AIM Management Effectiveness >> Compare AIM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 132
Sector	# 864
Overall	# 4461

Return On Assets Statistics
High	Average	Low
6.48 %	-95.15 %	-257.85 %
(Jan 31 2013)		(Dec 31 2025)

Financial Statements
Aim Immunotech Inc 's Assets	$ 9 million	AIM's Balance sheet
Aim Immunotech Inc 's Income	$ -3 million	Quarterly AIM's Income Statement
AIM's Income by Division		See AIM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-32.83 %	-55.59 %	-52.13 %	-29.83 %	150.48 %
Total Assets in million	6	9	19	40	58
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-14	-17	-29	-19	-19
Annual Return On Assets	-241.4 %	-201.21 %	-149.44 %	-48.03 %	-33.15 %

AIM's 5 Years Annual ROA >> Back to AIM Management Effectiveness >> Compare AIM ROA to its Competitors

More Return On Assets Ratios
AIM's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AIM's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AIM's Competitors
Subscribers only: Roa for Aim Immunotech Inc 's Suppliers
Subscribers only: Return On Assets for AIM's Customers

You may also want to know
AIM's Roi	AIM's Inventory Turnover Ratio	AIM's Growth Rates	AIM's Dividend Comparisons
	AIM's Profitability Ratios	AIM's Asset Turnover Ratio	AIM's Dividend Growth
AIM's Roe	AIM's Valuation Ratios	AIM's Financial Strength Ratios	AIM's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.